Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
  • SLE Clinical Trials (Lupus)

divider

Lupus butterfly icon

Systemic LUPUS Erythematosus (SLE) Studies Now Recruiting

See if you might be eligible by answering a few questions
Check Your Eligibility

divider

Study Purpose

 

POETYK SLE-1 (IM011-246) and POETYK SLE-2 (IM011-247) are two identical SLE clinical trials evaluating the safety and effectiveness of an investigational study medication in adults with active systemic lupus erythematosus (SLE). 

Participants will be randomly assigned to receive either the study medication or a placebo.  All participants will continue to take their usual lupus treatment while on study medication. The study medication (or placebo) is one tablet taken by mouth twice daily.

If you are eligible, you would only participate in one of these two studies.

Remember: Taking part in a clinical trial is voluntary, and if you enroll, you can choose to leave the study at any time.

Trial Details

  • Phase 3

    Phase

  • Gender(s)

  • 18-75

    Age Range

  • 14 Visits over 56 Weeks

    Screening and Double-Blind Treatment

  • 12 Visits over 2 Years

    Long-Term Extension

  • 1 Visit

    Folllow Up

Have a Question?

Visit Our Frequently Asked Questions for Clinical Trials
Visit FAQs

Who may participate in these studies?

Who may participate in these studies?

You may qualify for one of these research studies, if the following eligibility criteria are met:

  • 18 to 75 years of age
  • Diagnosed with SLE 
  • Currently have a rash and/or arthritis due to lupus
  • Positive antibodies (ANA, or anti-dsDNA or anti-Smith) based on lab screening
  • On treatment for lupus with an anti-malarial, an immunosuppressant medication, or one of each
  • No other autoimmune disease except type 1 diabetes mellitus, thyroid autoimmune disease, celiac disease, or secondary Sjogren’s syndrome

Additional eligibility criteria will be explained to you by the study doctor.

Study Stages

divider

Compensation

If you are eligible for one of these SLE studies and choose to join, you will receive the study medication while enrolled in the study. You will not be responsible for study-related costs such as visits, lab tests and procedures. You may also be eligible for reimbursement for some costs, such as travel or transportation expenses. Your study team can provide additional information.

divider

Trial Site Locations in North and South America

Map for study sites in the America
View List of All Sites

divider

The map above only shows study sites in the Americas. If you are searching for a study site outside of the Americas, please click on the View List of All Sites button and enter your location.

divider

A Commitment to Increasing Diversity

A Commitment to Increasing Diversity

Bristol Myers Squibb is united by our mission to transform patient’s lives through science by discovering, developing, and delivering innovative medicines that help prevail over serious diseases. To that end, we are committed to doing our part to help ensure patients have a fair and just opportunity to achieve optimal health outcomes.

We are working to improve the recruitment of diverse patients with the goal that the clinical trial population becomes more reflective of the real-world population and the people impacted by the diseases studied.

Check your eligibilityCheck Your Eligibility